NBTY Prefers Strategic Over "Easy" Acquisitions, Looks To China
This article was originally published in The Tan Sheet
Executive Summary
NBTY looks to continue making strategic rather than "easy" acquisitions and includes China in its target markets, President Harvey Kamil says
You may also be interested in...
Sales & Earnings In Brief
NBTY realizes income leap post Leiner integration: First-quarter net income soars 461 percent to $75.6 million from $13.5 million - or $1.18 diluted earnings per share compared to 21 cents - as NBTY put the costs of integrating Leiner Health Products behind it. Additionally, former Leiner customers that looked elsewhere for private-label manufacturing before NBTY acquired the firm have largely returned, said CEO Scott Rudolph during a Jan. 28 earnings call. "Much of the business has come back absolutely and some of it is on the way back," Rudolph said. The Ronkonkoma, N.Y.-based supplement firm reported net sales of $751.2 million in the October-December period, a jump of 13.8 percent. NBTY's wholesale/U.S. nutrition business expanded 15.8 percent to $471.1 million, and Rudolph said the company is in the early stages of expanding some of its domestic brands overseas. The European retail operation grew 12.8 percent to $176 million in the quarter as NBTY continued integrating the U.K. Julian Graves stores (1"The Tan Sheet" Nov. 30, 2009)
NBTY Not "Trigger Happy," But Acquisitions Stay In Its Crosshairs
NBTY hopes to remain a supplement industry giant in part by continuing to acquire other businesses, a strategy with an improving outlook as opportunities emerge during the global economic slump
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC